Medications That Cause Weight Gain

Medication-associated weight gain is common, clinically meaningful, and often preventable. It can worsen cardiometabolic risk, reduce adherence, and complicate long-term disease management. Contemporary reviews emphasise two key points: (i) weight effects vary substantially within drug classes (especially psychotropics), and (ii) “weight gain” may reflect fat mass gain, fluid retention, or reversal of energy loss (e.g., reduced glycosuria after improved glycaemic control), which matters for management strategies. (1,2)

1. Defining “weight gain” in pharmacotherapy

Weight increases after starting or changing therapy may represent:

• Increased adiposity (true fat mass gain), typically from increased appetite and/or reduced energy expenditure. (1)

• Fluid retention (rapid weight increases without proportional fat gain), classically relevant for systemic glucocorticoids and some glucose-lowering drugs. (8)

• Reduced energy loss after improved glycaemia (e.g., insulin or insulin secretagogues), where less glucose is lost in urine and net energy retention rises. (6,7)

• Secondary effects that reduce activity (sedation, fatigue), contributing to positive energy balance. (1,2)

Clinically, distinguishing these patterns helps target interventions (e.g., nutrition counselling vs assessing oedema or revising a regimen). (1,8)

2. Mechanisms

Across medication classes, several recurring pathways explain weight gain:

• Appetite stimulation and altered satiety signalling, particularly via central neurotransmitter pathways (common in psychotropics and some antihistamines). (1,2)

• Reduced energy expenditure and physical activity, often mediated by sedation or reduced exercise tolerance. (1,2)

• Increased insulin availability or insulin action, which promotes substrate storage and reduces glycosuria in diabetes. (6,7)

• Fluid retention and body-composition shifts, important for systemic glucocorticoids and some metabolic drugs. (8)

3. Medicines most consistently associated with weight gain (summary table)

Psychotropics

Antipsychotics show the strongest and most heterogeneous weight-gain liability among commonly prescribed medicines. In comparative evidence, olanzapine and clozapine consistently rank among the highest-risk agents, while several others (e.g., aripiprazole, lurasidone, ziprasidone) are generally more weight-neutral. (3)

Antidepressants also differ meaningfully by agent. In large comparative real-world analyses of first-line antidepressants, bupropion shows the least weight gain, while several SSRIs/SNRIs show small but measurable increases relative to sertraline over months. (4) Broader syntheses further support between-drug differences across multiple physiological outcomes. (5)

Mood stabilisers / anticonvulsants / neuropathic pain agents: contemporary psychiatric reviews highlight differential weight-gain liability within anticonvulsants and continued relevance of agents such as lithium and valproate for weight gain risk in practice (agent- and patient-dependent). (2)

Glucose-lowering therapies (type 2 diabetes)

Current standards in the USA and widely used guidance in Australia emphasise that insulins, sulfonylureas, and thiazolidinediones can promote weight gain and should be used judiciously—particularly in people with overweight/obesity—while weight-loss–promoting options may be prioritised when clinically appropriate. (6,7)

Systemic corticosteroids

Systemic glucocorticoids can cause early weight increases through fluid retention and later through appetite increase and metabolic effects, with risk shaped by dose and duration. (8)

H1 antihistamines

Evidence (including observational paediatric data) links antihistamine exposure with increases in BMI trajectories; sedating H1 antihistamines are commonly considered higher-risk due to appetite/sedation effects, though causality and effect size can vary by population and indication. (1,9)

Depot medroxyprogesterone acetate

Depot medroxyprogesterone acetate (DMPA) is associated with weight gain in some cohorts; susceptibility varies, and earlier initiation age may be associated with larger gains in certain populations. (10)

Beta-blockers

Beta-blockers are included among medication classes implicated in weight gain in recent broad reviews, with effects generally described as modest and variable by agent and patient context. (1) Mechanistic reviews also discuss the broader metabolic effects relevant to weight change. (11)

Antiretroviral therapy (ART)

Modern ART-associated weight gain has become a prominent topic in HIV care. Australian HIV guidance (aligned with DHHS source updates and local commentary) notes that initiation of INSTI-containing regimens has been associated with greater weight increases versus some alternative regimen classes, and that weight gain may be greater with TAF than other NRTIs; effects may be more pronounced in women and some ethnic groups. (12) A recent endocrine review summarises proposed mechanisms and implications of ART-associated weight gain. (13)